The RTS,S malaria vaccine: Current impact and foundation for the future-Reference-Cited by-同舟云学术

The RTS,S malaria vaccine: Current impact and foundation for the future

Published:2022-11-16 Issue:671 Volume:14 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Beeson James G.¹²³^ORCID,Kurtovic Liriye¹³^ORCID,Valim Clarissa⁴,Asante Kwaku Poku⁵,Boyle Michelle J.⁶⁷⁸^ORCID,Mathanga Don⁹,Dobano Carlota¹⁰¹¹^ORCID,Moncunill Gemma¹⁰¹¹^ORCID

Affiliation:

1. Burnet Institute, Melbourne 3004, Victoria, Australia.

2. Department of Infectious Diseases, University of Melbourne, Victoria, Australia.

3. Monash University, Central Clinical School and Department of Microbiology, Victoria, Australia.

4. Department of Global Health, Boston University School of Public Health, Boston, MA, USA.

5. Kintampo Health Research Centre, Kintampo North Municipality, Bono East Region, Ghana.

6. QIMR Berghofer Institute, Herston, Queensland, Australia.

7. University of Queensland, School of Biomedical Sciences, St Lucia, Queensland, Australia.

8. Griffith University, Brisbane, Queensland, Australia.

9. Malaria Alert Centre, Kamuzu University of Health Sciences, Blantyre, Malawi.

10. ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia, Spain.

11. CIBER Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

Abstract

The RTS,S vaccine has recently been recommended for implementation as a childhood vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of vaccine protection and longevity, implementation considerations, and future research needed to increase the vaccine’s health impact, including vaccine modifications for higher efficacy and longevity of protection.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference50 articles.

1. World Health Organization World Malaria report 2021; www.who.int/publications/i/item/9789240040496.

2. The economic and social burden of malaria

3. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

4. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

5. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria;Vaccines;2024-02-06

2. Assessing the Implementation Determinants of Pilot Malaria Vaccination Programs in Ghana, Kenya, and Malawi through a Complexity Lens: A Rapid Review Using a Consolidated Framework for Implementation Research;Vaccines;2024-01-23

3. Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate;Expert Review of Vaccines;2023-12-27

4. Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond;Expert Review of Vaccines;2023-12-14

5. The many paths to artemisinin resistance in Plasmodium falciparum;Trends in Parasitology;2023-12